Abstract

Simple SummaryYounger age has been associated with better overall survival in Ewing sarcoma, especially under the age of 10. Our study aimed at describing long-term outcomes of a cohort of 60 patients aged 0–10 with Ewing sarcoma, treated with chemotherapy, surgery and/or radiotherapy. Overall survival of these youngest patients with ES was very good. After 10 years, 81% of patients were still alive, 89% did not have a local recurrence and 81% did not have distant metastasis (in lungs and/or bone). Limb salvage surgery was achieved in >90% of patients. Wide resection margin was the only factor significantly associated with better survival, but age < 6 years, smaller tumors, no metastases at diagnosis and treatment after 2000 also seemed to result in better overall survival.(1) Background: Younger age has been associated with better overall survival (OS) in Ewing sarcoma (ES), especially under the age of 10. The favorable survival in younger patients underlines the need for minimizing treatment burden and late sequelae. Our study aimed at describing clinical characteristics, treatment and outcome of a cohort of ES patients aged 0–10. (2) Methods: In this retrospective multicenter study, all consecutive ES patients aged 0–10, treated in four sarcoma centers in the Netherlands (n = 33) and one in Spain (n = 27) between 1982 and 2008, with a minimum follow-up of 10 years, were included. OS, local recurrence-free survival (LRFS) and distant metastasis-free survival (DMFS) were calculated. Potential factors of influence on OS (risk and protective factors) were analyzed. (3) Results: 60 patients with median follow-up 13.03 years were included. All patients were treated with chemotherapy in combination with local treatment, being surgery alone in 30 (50%) patients, radiotherapy (RT) alone in 12 (20%) patients or surgery plus RT in 18 (30%) patients (12 pre- and 6 postoperative). Limb salvage was achieved in 93% of patients. The 10-OS, -LRFS and -DMFS are 81% (95% CI: 71–91%), 89% (95% CI: 85–93%) and 81% (95% CI: 71–91%), respectively. Six patients developed LR, of which two developed subsequent DM; all had axial ES (pelvis, spine or chest wall), and these patients all died. Ten patients developed DM; eight died due to progressive disease, and two are currently in remission, both with pulmonary metastasis only. Negative or wide resection margin was significantly associated with better OS. Age < 6 years, tumor volume < 200 mL, absence of metastatic disease and treatment after 2000 showed trends towards better OS. Two patients developed secondary malignancy; both had chemotherapy combined with definitive RT for local treatment. (4) Conclusions: Overall survival of these youngest patients with ES was very good. Limb salvage surgery was achieved in >90% of patients. Wide resection margin was the only factor significantly associated with better survival.

Highlights

  • Ewing sarcoma (ES) is an aggressive bone and soft-tissue tumor predominantly affecting children and young adults [1–4]

  • All patients were treated with a combination of chemotherapy and local tumor treatment, being either surgery, radiotherapy or both

  • Treatment and outcomes of a cohort of 60 Ewing sarcoma patients aged 0–10 with a minimum follow-up of 10 years

Read more

Summary

Introduction

Ewing sarcoma (ES) is an aggressive bone and soft-tissue tumor predominantly affecting children and young adults [1–4]. Fifteen to 20% of patients are aged between 0 and 10 years at time of diagnosis [5–7]. Advances in multimodal treatment of Ewing sarcoma have gradually improved survival to a 10-year overall survival (OS) of 70–75% in nonmetastatic Ewing sarcoma. Survival in metastatic Ewing sarcoma remains poor, with a 5-year OS of 20–35% [8–10]. Known risk factors for worse outcome in Ewing sarcoma are primary tumors located in the pelvis or spine [11–15] and chest wall [16,17], as well as large tumor volume (>200 mL) and size (>8 cm) [18–21] and presence of metastatic disease [3,22,23]. Patients with extrapulmonary metastases do significantly worse than patients with pulmonary metastases alone [8,19,24]. In multivariate analyses, younger age has been associated with a better clinical outcome, especially under the age of 10 [12,19,22,24,25]

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call